Caribou Biosciences Inc
CRBU
View Detailed Chart
1.570USD
+0.090+6.08%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
146.74MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+6.08%
5 Days
+11.35%
1 Month
-8.72%
6 Months
-16.49%
Year to Date
-1.26%
1 Year
+10.56%
View Detailed Chart
TradingKey Stock Score of Caribou Biosciences Inc
Currency: USD Updated: 2026-02-06Key Insights
Caribou Biosciences Inc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 108 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 11.11.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Caribou Biosciences Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Caribou Biosciences Inc Highlights
StrengthsRisks
Caribou Biosciences, Inc. is a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company engaged in developing transformative therapies for patients with devastating diseases. The Company’s genome-editing platform, including its Cas12a chRDNA technology, enables superior precision to develop cell therapies that are armored to potentially improve activity against disease. Caribou is advancing a pipeline of off-the-shelf cell therapies from its CAR-T platform to offer broad access and rapid availability of treatments for patients with hematologic malignancies and autoimmune diseases. Its genome-editing platform, including its novel chRDNA technology, enables more precise genome editing of allogeneic cell therapies. It is advancing its pipeline of allogeneic CAR-T cell therapies with clinical development programs targeting the treatment of hematologic malignancies and autoimmune diseases.
Growing
The company is in a growing phase, with the latest annual income totaling USD 9.99M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 9.99M.
Overvalued
The company’s latest PE is -0.93, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 36.52M shares, increasing 0.02% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 4.30M shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.40.
Analyst Rating
Based on
9
analysts
Buy
Current Rating
11.111
Target Price
+650.75%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Caribou Biosciences Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Caribou Biosciences Inc Info
Caribou Biosciences, Inc. is a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company engaged in developing transformative therapies for patients with devastating diseases. The Company’s genome-editing platform, including its Cas12a chRDNA technology, enables superior precision to develop cell therapies that are armored to potentially improve activity against disease. Caribou is advancing a pipeline of off-the-shelf cell therapies from its CAR-T platform to offer broad access and rapid availability of treatments for patients with hematologic malignancies and autoimmune diseases. Its genome-editing platform, including its novel chRDNA technology, enables more precise genome editing of allogeneic cell therapies. It is advancing its pipeline of allogeneic CAR-T cell therapies with clinical development programs targeting the treatment of hematologic malignancies and autoimmune diseases.
Ticker SymbolCRBU
CompanyCaribou Biosciences Inc
CEOHaurwitz (Rachel E)
Websitehttps://www.cariboubio.com/
Related Instruments
+3.66%
+3.17%
+0.93%
+1.99%
+1.78%
+1.60%
-0.95%
+4.49%
+2.10%
+10.00%
+2.72%
+4.15%
+1.81%
+4.17%
+0.72%
+1.06%
+2.46%
0.00%
+0.53%
+0.56%Popular Symbols
278.120
+2.210 (+0.80%)
185.410
+13.530 (+7.87%)
69607.650
-362.480 (-0.52%)
282.580
+22.390 (+8.61%)
2061.140
+9.410 (+0.46%)
411.110
+13.900 (+3.50%)
4952.980
+142.360 (+2.96%)
63.303
+0.206 (+0.33%)
1.182
+0.004 (+0.35%)
157.098
+0.057 (+0.04%)
